Skip to content
10-K

Annual Report

APTEVO THERAPEUTICS INC. APVO

0001193125-26-126278

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 26, 2026 1.18M sh
Shares Diluted FY 2025 · Dec 31, 2025 315.54K sh
Shares Diluted restated FY 2025 · Dec 31, 2024 767 sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$25.59M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$23.79M
Cash And Equivalents FY 2025 · Dec 31, 2025 $21.62M
Cash And Equivalents FY 2025 · Dec 31, 2024 $8.71M
Stockholders Equity FY 2025 · Dec 31, 2025 $17.38M
Stockholders Equity FY 2025 · Dec 31, 2024 $4.76M
Stockholders Equity FY 2025 · Dec 31, 2023 $12.22M
Current Liabilities FY 2025 · Dec 31, 2025 $6.05M
Current Liabilities FY 2025 · Dec 31, 2024 $6.21M
Total Liabilities FY 2025 · Dec 31, 2025 $9.81M
Total Liabilities FY 2025 · Dec 31, 2024 $10.84M
Current Assets FY 2025 · Dec 31, 2025 $23.08M
Current Assets FY 2025 · Dec 31, 2024 $10.66M
Total Assets FY 2025 · Dec 31, 2025 $27.19M
Total Assets FY 2025 · Dec 31, 2024 $15.59M
Eps Diluted FY 2025 · Dec 31, 2025 −$87.27
Eps Diluted restated FY 2025 · Dec 31, 2024 −$31,460.23
Eps Basic FY 2025 · Dec 31, 2025 −$87.27
Eps Basic restated FY 2025 · Dec 31, 2024 −$31,460.23
Rd Expense FY 2025 · Dec 31, 2025 $14.54M
Rd Expense FY 2025 · Dec 31, 2024 $14.38M
Net Income FY 2025 · Dec 31, 2025 −$25.97M
Net Income FY 2025 · Dec 31, 2024 −$24.13M
Operating Income FY 2025 · Dec 31, 2025 −$26.31M
Operating Income FY 2025 · Dec 31, 2024 −$24.6M